Teva Pharmaceutical Industries (TEVA) Total Debt (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Total Debt for 18 consecutive years, with $16.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Debt fell 3.69% year-over-year to $16.6 billion; the trailing twelve-month figure through Jun 2026 stood at $16.6 billion (down 3.69% YoY), and the FY2025 full-year result was $16.8 billion, down 5.49% from the prior year.
• Total Debt held at $16.6 billion in Q2 2026 per TEVA's latest filing, from $16.6 billion in the prior quarter.
• Across five years, Total Debt topped out at $22.9 billion in Q1 2022 and bottomed at $16.6 billion in Q2 2026.
• Historically, Total Debt has averaged $19.1 billion across 5 years, with a median of $19.3 billion in 2024.
• The sharpest annual moves came in 2025 and 2026: Total Debt slipped 15.24% in 2025, then fell 0.14% in 2026.
• Over 5 years, Total Debt stood at $21.2 billion in 2022, then decreased by 6.5% to $19.8 billion in 2023, then decreased by 10.34% to $17.8 billion in 2024, then decreased by 5.49% to $16.8 billion in 2025, then declined by 1.27% to $16.6 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $16.6 billion, $16.6 billion, and $16.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.